Clinical trial

Prophylaxis of Hematologic Complications With Naderin in First-Line Breast Cancer Chemotherapy

NCT07671547

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2014-01-01

PhasePHASE2 / PHASE3

Study timeline

Study start (actual)2014-01-01Date precision: day

Registry last updated2026-06-30

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Breast Cancerunresolved

Hematologic Disorderunresolved

Leukopeniaunresolved

Chemotherapy-Induced Myelosuppressionunresolved

Interventions

NaderinDRUG

AC ChemotherapyDRUG

Sponsors & collaborators

MIPO Cliniclead sponsor

Asfendiyarov Kazakh National Medical Universitycollaborator

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT07671547 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.